Predict your next investment

Aelix Therapeutics company logo
HEALTHCARE | Drug Development
aelixtherapeutics.com

See what CB Insights has to offer

Stage

Grant | Alive

Total Raised

$12.57M

Last Raised

$60K | 4 yrs ago

About Aelix Therapeutics

Aelix Therapeutics is a drug development company that specializes in the discovery and development of immunotherapies against HIV infection.

Aelix Therapeutics Headquarter Location

Barcelona,

Spain

Latest Aelix Therapeutics News

AELIX Therapeutics appoints Dr Melanie Rolli as CEO

May 18, 2021

AELIX Therapeutics appoints Dr Melanie Rolli as CEO Dr Rolli will support the company’s vision of positioning HTI vaccines for future functional cure strategies. In her new role, Dr Rolli will lead Aelix through the next growth stage – progressing the company’s aim of bringing therapeutic vaccines to HIV patients. (‘AELIX’), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces the appointment of Dr Melanie Rolli as chief executive officer, following the decision of her predecessor, Dr José Luis Cabero, to step down from executive positions at Aelix. Dr Rolli brings a wealth of knowledge to her new role as CEO – with decades of hands-on experience in the pharmaceutical sector, including various positions of increasing responsibility whilst at Novartis. Dr Rolli said: “I’m excited to join a high-performing team that has achieved a major milestone by translating a biological concept into positive clinical results with their first clinical trial. Our goal now is to advance the program and bring an innovative HIV functional cure therapy to patients.” This appointment follows the company’s March 2021 announcement of positive topline results in the AELIX-002 Phase I/II clinical trial . The strong data represent a major breakthrough development in the field and the results support Aelix’s plans for larger combination trials. “We are delighted to welcome Dr Melanie Rolli to the team. Her invaluable experience and key skills will further support our ambitions, steer our growth and direct our development programs. We look forward to the next chapter under Melanie’s leadership,” said Dr. Thomas Hecht, chairman of Aelix’ board of directors. “We also want to express a big thank you to José Luis for steering the ship over the last few years,” Dr. Hecht added. The positive results from the clinical trial support further development of combination strategies based on the HTI vaccine, with the aim of controlling HIV without the need for continued antiretroviral medication. Aelix plans to rapidly conduct multiple clinical trials including the ongoing collaboration phase II study with Gilead Sciences that combines the HTI vaccine with the TLR-7 agonist Vesatolomid. The appointment of Dr Rolli will support Aelix’s vision of positioning HTI vaccines for future cure strategies and becoming the front-runner in HIV treatment by bringing a therapeutic vaccine to the market. Notes to editor on Dr Melanie Rolli: Previously held the position of CEO at PIQUR Therapeutics AG in Basel, Switzerland; a clinical stage biotech company focusing on the development of new medications in the fields of oncology and dermatology Currently holds non-executive director positions at Mundipharma, Erytech and Baccinex Before PIQUR, Dr Rolli was at Novartis Pharmaceutical AG for 14 years, where she held positions of increasing responsibility in global development, global safety and medical affairs Received her medical education at the University of Heidelberg, Germany. Earning a doctorate in pharmacology magna cum laude Completed her post-doctoral training at the SCRIPPS Research Institute in La Jolla (CA, USA), spent a decade in the US About AELIX Therapeutics AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen. The company is backed by a syndicate of experienced Spanish and international investors.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aelix Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aelix Therapeutics is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

B

Biopharmaceuticals

5,732 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

I

Infectious Disease

2,226 items

Entities aiding the surveillance, screening, prevention, diagnosis, treatment, and containment of infections & the maintenance of public wellbeing during outbreaks.

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Aelix Therapeutics Patents

Aelix Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • HIV/AIDS
  • Immunology
  • Lentiviruses
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/12/2020

HIV/AIDS, Transcription factors, Viral proteins, Lentiviruses, Immunology

Application

Application Date

11/12/2020

Grant Date

Title

Related Topics

HIV/AIDS, Transcription factors, Viral proteins, Lentiviruses, Immunology

Status

Application

Aelix Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aelix Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.